IF Nutlin-3b (estimated ~25 mg/kg based on Kondoh lab Research Context dosing, oral gavage, intermittent 5-days-on/9-days-off schedule) is co-administered with sub-therapeutic ABT-263 (navitoclax, ~12.5 mg/kg oral gavage — half the standard senolytic dose of 25 mg/kg) to 20-month-old male C57BL/6J mice with bleomycin-induced pulmonary fibrosis,

THEN senescent cell burden (p16INK4a+ cells, SA-β-gal activity, p21 expression) will be reduced by ≥50% greater than either monotherapy alone, lung fibrosis (Ashcroft score) will be attenuated by ≥40% versus vehicle, and systemic thrombocytopenia (the primary dose-limiting toxicity of ABT-263 at full dose) will remain below the threshold of clinical significance (platelet count >600 × 10³/µL),

BECAUSE the PGAM-Chk1-FoxM1-BIM axis and the BCL-XL-BIM sequestration axis represent two independent, non-overlapping survival barriers in senescent cells that converge on the pro-apoptotic effector BIM — and simultaneous disruption of both barriers creates a senescence-selective synthetic lethality:

1. Senescent cells upregulate PGAM1 and establish a non-canonical PGAM1–Chk1 protein–protein interaction that stabilizes Chk1, preventing its ubiquitination and proteasomal degradation; this Chk1 stability drives FoxM1 transcriptional activity, which suppresses BIM expression at the mRNA level, allowing senescent cells to survive despite persistent DNA damage (Research Context — Kondoh lab, 2025/2026) [SPECULATIVE: full IC50 data for PGAM-Chk1 disruption by Nutlin-3b not yet published in peer-reviewed form accessible in this Evidence Set].

2. Nutlin-3b binds PGAM1 and displaces Chk1, triggering Chk1 degradation, collapsing FoxM1-mediated BIM transcriptional repression, and thereby increasing cytoplasmic BIM protein. However, the liberated BIM can be sequestered by BCL-XL or BCL-2 at the mitochondrial outer membrane, blunting the apoptotic signal in a subset of senescent cells (Research Context; mechanism of BIM sequestration by BCL-family proteins is directly demonstrated in the ABT-263 senolysis paper) (ABT-263 sequesters BIM via BCL-XL–BAX axis in senescent tumor cells)[https://doi.org/10.1002/1878-0261.12761].

3. BCL-XL is upregulated in therapy-induced and naturally senescent cells as part of the senescent survival network, where it captures and neutralizes pro-apoptotic BIM protein at the mitochondrial membrane, representing a downstream resistance node to any upstream BIM-liberating intervention (BCL-XL is the dominant survival factor in senescent tumor cells, and ABT-263 disrupts BCL-XL–BAX interaction to drive senolysis)[https://doi.org/10.1002/1878-0261.12761].

4. Sub-therapeutic ABT-263 (12.5 mg/kg) frees BIM from BCL-XL sequestration, but at this sub-threshold dose is insufficient to trigger apoptosis in senescent cells that still have FoxM1-driven BIM transcriptional suppression intact — meaning BIM levels are low and BCL-XL inhibition alone cannot drive commitment to apoptosis. The co...

SENS category: MitoSENS

Key references: • doi.org/10.1002/1878-0261.12761]. • doi.org/10.1101/gad.331272.119]. • doi.org/10.1002/1878-0261.12761] • doi.org/10.1101/gad.271882]. • doi.org/10.1101/gad.331272.119];